RxDoctor Payments Data

Monique Joseph

Family · Locust Grove, GANPI 1669038303

Payments from drug & device makers

$7,593in general payments, 2019–2025

Across 471 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$941
  • AbbVie$882
  • Lilly USA, LLC$854
  • AstraZeneca$737
  • GSK$549
  • Pfizer$407
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,593100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,593 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$18,845
Medicare patients
96
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$29,322
OzempicSemaglutide19$25,941
JardianceEmpagliflozin12$16,462
BriviactBrivaracetam11$15,741
KerendiaFinerenone13$11,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,252
Albuterol Sulfate HfaAlbuterol Sulfate101$2,440
Gabapentin53$871
Atorvastatin Calcium109$827
Omeprazole61$748
Ondansetron OdtOndansetron34$722
Venlafaxine Hcl ErVenlafaxine Hcl35$676
Diclofenac Sodium40$610
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine19$609
Alprazolam104$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$854$29,32226 claims
Novo NordiskOzempic$941$25,94119 claims
Boehringer IngelheimJardiance$62$16,46212 claims
BayerKerendia$162$11,41813 claims
GSKTrelegy Ellipta$549$10,25217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Locust Grove

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →